1110766-97-6

Basic information

• Product Name: Lusutrombopag
• Synonyms: S888711;S 888711;S888711;S 888711;Lusutrombopag S-888711;(E)-3-[2,6-dichloro-4-[4-[3-[(S)-1-hexyloxyethyl]-2-methoxyphenyl]thiazol-2-ylcarbamoyl]phenyl]-2-methylacrylic acid;2-Propenoic acid, 3-[2,6-dichloro-4-[[[4-[3-[(1S)-1-(hexyloxy)ethyl]-2-methoxyphenyl]-2-thiazolyl]amino]carbonyl]phenyl]-2-methyl-, (2E)-
• CAS NO: 1110766-97-6
• Molecular Formula: C₂₉H₃₂Cl₂N₂O₅S
• Molecular Weight: 591.54578
• EINECS: -0
• Product Categories: API
• Mol File: 1110766-97-6.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Density: 1.299±0.06 g/cm3(Predicted)
• PKA: 4.33±0.21(Predicted)
• CAS DataBase Reference: Lusutrombopag(CAS DataBase Reference)
• NIST Chemistry Reference: Lusutrombopag(1110766-97-6)
• EPA Substance Registry System: Lusutrombopag(1110766-97-6)

Safety Data

• Hazardous Substances Data: 1110766-97-6(Hazardous Substances Data)

Usage

Uses

Lusutrombopag is a newly discovered thrombopoietin receptor agonist used in the treatment of patients with chronic ITP.

Upstream product

• 1110768-00-7 (S,E)-ethyl 3-(2,6-dichloro-4-((4-(3-(1-(hexyloxy)ethyl)-2-methoxyphenyl)thiazol-2-yl)carbamoyl)phenyl)-2-methylacrylate 

Relevant articles and documents

Brand new synthesis technology of lusutrombopag

The invention relates to the field of organic chemistry, and especially relates to a brand new synthesis technology of lusutrombopag. The technology comprises the following steps: preparing an intermediate 3-(2-aminothiazolyl-4-yl)-2-methoxyacetophenone (4) from 2-methoxy-1,3-diacetylbenzene, reacting 3-(2-aminothiazolyl-4-yl)-2-methoxyacetophenone (4) with methyl (E)-ethyl-3-(2,6-dichloro-4-(chloroformyl)phenyl)-2-acrylate (5) to obtain a key intermediate methyl (E)-ethyl-3-(4-((4-(3-acetyl-2-methoxyphenyl)thiazolyl-2-yl)carbamoyl)-2,6-dichlorophenyl)-2-acrylate (6), carrying out catalytic reduction on the key intermediate, carrying out a halogenations reaction, and carrying out a hydrolysis reaction to obtain the target compound lusutrombopag. The technology has the advantages of easily available raw material, mild reaction conditions, simplicity in operation, good stability and activity of a catalyst, high total yield, and convenience for large-scale preparation and production of lusutrombopag.